Degron Therapeutics closed a $40 million Series A extension round to accelerate its molecular glue degraders program. The company said it will advance degraders designed to hit proteins that are either traditionally “undruggable” or insufficiently targeted by current modalities. The funding underscores ongoing investor appetite for targeted protein degradation platforms, particularly approaches aimed at expanding the druggable space. Degron’s emphasis on molecular glues positions it within a competitive but fast-moving modality category. The extension round also signals confidence in preclinical or early development progress sufficient to bring forward additional discovery and development work.